All posts by: Michael Zand

About Michael Zand

Prescribed Reading: CRISPR, Trump and FOURIER. Oh my! – BioPharma Dive

Continue reading

2017-03-17 NEWS

Prescribed Reading: CRISPR, Trump and FOURIER. Oh my!
BioPharma Dive
Allergan is giving people one more reason to keep a close eye on CRISPR. The specialty pharma has teamed up with Editas Medicine to develop its eye-disease candidates, including the Cambridge biotech’s lead program in Leber Congenital Amaurosis …

Continue reading

2017-03-17 NEWS

Computational Analysis of Immunotherapy Response Paints a Complex Picture
Immuno-Oncology News
Using an advanced computational analysis may help scientists predict which patients are likely to respond to immunotherapy. But researchers — who hope a more integrated picture of the immune response might advance immunotherapy strategies — say …

Continue reading

2017-03-17 NEWS

Computational Analysis of Immunotherapy Response Paints a Complex Picture
Immuno-Oncology News
Using an advanced computational analysis may help scientists predict which patients are likely to respond to immunotherapy. But researchers — who hope a more integrated picture of the immune response might advance immunotherapy strategies — say …

Continue reading

2017-03-17 NEWS

Cedars-Sinai, TransOmic Partner to Push AI-Driven CRISPR/Cas9 Design Tool to Market
GenomeWeb
NEW YORK (GenomeWeb) – Genomic screening firm TransOmic has partnered with researchers from Cedars-Sinai Medical Institute and Cold Spring Harbor Laboratory to offer a promising but unproven artificial intelligence-driven CRISPR/Cas9 guide RNA …

Continue reading

2017-03-17 NEWS

Retraction Watch (blog)

Two more retractions for stem cell researcher appealing her dismissal
Retraction Watch (blog)
Antonio Herrera-Merchan, a former postdoctoral researcher in Gonzalez’s lab at CNIC who co-authored the Cell Cycle paper and one of the two newly retracted papers in Nature Communications, told us he does not know what happened to the raw data after …